Juno is focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human T cells as therapeutics will drive one of the next important phases in medicine, we are developing cell-based cancer immunotherapies based on our chimeric antigen receptor (CAR) and high-affinity T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. We have shown compelling evidence of tumor shrinkage in clinical trials using multiple cell-based product candidates to address refractory B-cell lymphomas and leukemias. Longer term, Juno aims to develop our cell-based platform to include additional product candidates to address a broad range of cancers and human diseases.
Juno is led by a management team with diverse backgrounds and talents, with the common goal of revolutionizing medicine through developing a broadly applicable cell-based platform.
Board of Directors
The Juno Board of Directors is comprised of industry leaders with a track record of navigating novel science and building enduring companies.
Juno brings together some of the world’s leaders in oncology, immunology, and cell therapy who are pioneers in the CAR and TCR space.
Juno’s Scientific Advisors provide diversified expertise across our external advisory network.
Juno has partnered with world-leading medical and research organizations to advance a broad pipeline of novel immunotherapies.
Stay connected with the latest news about Juno Therapeutics.